FDA warned Cipla about unresolved albuterol inhaler delivery complaints and contamination in sterile manufacturing at its Indore site.
What happened
FDA inspected Cipla’s Indore, India, drug manufacturing facility from February 6 to February 17, 2023. It found inadequate investigations of about 3,000 Albuterol Sulfate Inhalation Aerosol complaints from April 2020 to December 2022 and about 2,000 more from January to August 2023, a failure to submit a Field Alert Report, contamination in sterile-process simulation runs with gram-negative microbes, environmental monitoring problems, and bags of scrap containing manufacturing records with Quality Assurance signatures. FDA said Cipla’s March 10, 2023 response was inadequate.
What FDA found
Cipla did not thoroughly investigate albuterol inhaler complaints or extend investigations to other potentially affected batches, and its corrective and preventive actions were inadequate.
21 CFR 211.192Cipla did not submit a Field Alert Report to FDA within three working days after learning of significant product deterioration or change in a distributed drug product.
section 505(k) of the FD&C Act; 21 CFR 314.81(b)(1)(ii)Cipla did not establish or follow adequate written procedures to prevent microbiological contamination of sterile drug products, including validation of aseptic and sterilization processes.
21 CFR 211.113(b)Cipla’s quality unit did not adequately oversee retention of current good manufacturing practice (CGMP) records, and original records were found in scrap intended for shredding.
21 CFR 211.22(d)
What FDA wants
FDA asks Cipla to provide independent assessments, remediation plans, retrospective reviews, risk assessments, and management strategies for its complaint, investigation, aseptic, environmental monitoring, and record systems. The letter text provided does not state a response deadline.
Who should pay attention
- patients and clinicians who rely on albuterol rescue inhalers
- companies that buy or distribute Cipla-made inhalers or sterile drugs
- quality and manufacturing teams at sterile drug facilities
This is a summary. Read the original letter on fda.gov.